Sign in
SLXNW Stock Price, Chart, Stats & News
Silexion Therapeutics Ltd.
Save
Silexion Therapeutics Ltd. (SLXNW) does not currently pay a dividend.
17,053
Market cap
–
Current P/E
–
Forward P/E
SLXNW chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.05% |
ROA | -165.10% |
ROE | -387.82% |
D/E | 0.18x |
Interest coverage ratio | -1292.44x |
SLXNW valuation
P/E | – |
P/S | – |
P/B | 0.03x |
P/CF | -0.01x |
P/FCF | -0.00x |
P/OCF | -0.01x |
PEG | -0.00x |
EV multiple | -0.48x |
About
Silexion Therapeutics LTD is a biopharmaceutical company focused on the discovery and development of RNA interference (RNAi)-based therapies and their delivery systems, specifically targeting aggressive solid tumors. The firm utilizes its proprietary LODER delivery platform for the treatment of these malignant growths. Its pipeline features SiG12D-LODER, which has successfully completed preclinical investigations and an open-label Phase I clinical trial for pancreatic cancer.
Similar securities
Based on sector and market capitalization
Report issue